Literature DB >> 18499210

Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.

Josh D Nelson1, Heather Kinkead, Florence M Brunel, Dan Leaman, Richard Jensen, John M Louis, Toshiaki Maruyama, Carole A Bewley, Katherine Bowdish, G Marius Clore, Philip E Dawson, Shana Frederickson, Rose G Mage, Douglas D Richman, Dennis R Burton, Michael B Zwick.   

Abstract

Following CD4 receptor binding to the HIV-1 envelope spike (Env), the conserved N-heptad repeat (NHR) region of gp41 forms a coiled-coil that is a precursor to the fusion reaction. Although it has been a target of drug and vaccine design, there are few monoclonal antibody (mAb) tools with which to probe the antigenicity and immunogenicity specifically of the NHR coiled-coil. Here, we have rescued HIV-1-neutralizing anti-NHR mAbs from immune phage display libraries that were prepared (i) from b9 rabbits immunized with a previously described mimetic of the NHR coiled-coil, N35(CCG)-N13, and (ii) from an HIV-1 infected individual. We describe a rabbit single-chain Fv fragment (scFv), 8K8, and a human Fab, DN9, which specifically recognize NHR coiled-coils that are unoccupied by peptide corresponding to the C-heptad repeat or CHR region of gp41 (e.g. C34). The epitopes of 8K8 and DN9 were found to partially overlap with that of a previously described anti-NHR mAb, IgG D5; however, 8K8 and DN9 were much more specific than D5 for unoccupied NHR trimers. The mAbs, including a whole IgG 8K8 molecule, neutralized primary HIV-1 of clades B and C in a pseudotyped virus assay with comparable, albeit relatively modest potency. Finally, a human Fab T3 and a rabbit serum (both non-neutralizing) were able to block binding of D5 and 8K8 to a gp41 NHR mimetic, respectively, but not the neutralizing activity of these mAbs. We conclude from these results that NHR coiled-coil analogs of HIV-1 gp41 elicit many Abs during natural infection and through immunization, but that due to limited accessibility to the corresponding region on fusogenic gp41 few can neutralize. Caution is therefore required in targeting the NHR for vaccine design. Nevertheless, the mAb panel may be useful as tools for elucidating access restrictions to the NHR of gp41 and in designing potential improvements to mimetics of receptor-activated Env.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18499210      PMCID: PMC2493441          DOI: 10.1016/j.virol.2008.04.005

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  103 in total

Review 1.  Mechanisms of viral membrane fusion and its inhibition.

Authors:  D M Eckert; P S Kim
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

2.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Authors:  Jacqueline D Reeves; Stephen A Gallo; Navid Ahmad; John L Miamidian; Phoebe E Harvey; Matthew Sharron; Stefan Pohlmann; Jeffrey N Sfakianos; Cynthia A Derdeyn; Robert Blumenthal; Eric Hunter; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

3.  Distribution and three-dimensional structure of AIDS virus envelope spikes.

Authors:  Ping Zhu; Jun Liu; Julian Bess; Elena Chertova; Jeffrey D Lifson; Henry Grisé; Gilad A Ofek; Kenneth A Taylor; Kenneth H Roux
Journal:  Nature       Date:  2006-05-24       Impact factor: 49.962

4.  Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display.

Authors:  Mikhail Popkov; Rose G Mage; Cornelius B Alexander; Sujatha Thundivalappil; Carlos F Barbas; Christoph Rader
Journal:  J Mol Biol       Date:  2003-01-10       Impact factor: 5.469

5.  Kinetic dependence to HIV-1 entry inhibition.

Authors:  H Kirby Steger; Michael J Root
Journal:  J Biol Chem       Date:  2006-06-27       Impact factor: 5.157

6.  Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.

Authors:  Pascal Poignard; Maxime Moulard; Edwin Golez; Veronique Vivona; Michael Franti; Sara Venturini; Meng Wang; Paul W H I Parren; Dennis R Burton
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

7.  A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

Authors:  G Stiegler; R Kunert; M Purtscher; S Wolbank; R Voglauer; F Steindl; H Katinger
Journal:  AIDS Res Hum Retroviruses       Date:  2001-12-10       Impact factor: 2.205

8.  Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.

Authors:  Vidita Choudhry; Mei-Yun Zhang; Ilia Harris; Igor A Sidorov; Bang Vu; Antony S Dimitrov; Timothy Fouts; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2006-08-04       Impact factor: 3.575

9.  The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent.

Authors:  Marc Kirschner; Val Monrose; Maciej Paluch; Nipa Techodamrongsin; Axel Rethwilm; John P Moore
Journal:  Protein Expr Purif       Date:  2006-03-15       Impact factor: 1.650

10.  Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody.

Authors:  Micah A Luftig; Marco Mattu; Paolo Di Giovine; Romas Geleziunas; Renee Hrin; Gaetano Barbato; Elisabetta Bianchi; Michael D Miller; Antonello Pessi; Andrea Carfí
Journal:  Nat Struct Mol Biol       Date:  2006-07-23       Impact factor: 15.369

View more
  34 in total

1.  Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.

Authors:  Elisabetta Bianchi; Joseph G Joyce; Michael D Miller; Adam C Finnefrock; Xiaoping Liang; Marco Finotto; Paolo Ingallinella; Philip McKenna; Michael Citron; Elizabeth Ottinger; Robert W Hepler; Renee Hrin; Deborah Nahas; Chengwei Wu; David Montefiori; John W Shiver; Antonello Pessi; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-18       Impact factor: 11.205

2.  Efficient recovery of high-affinity antibodies from a single-chain Fab yeast display library.

Authors:  Laura M Walker; Diana R Bowley; Dennis R Burton
Journal:  J Mol Biol       Date:  2009-04-16       Impact factor: 5.469

3.  Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Authors:  Donna L Montgomery; Ying-Jie Wang; Renee Hrin; Micah Luftig; Bin Su; Michael D Miller; Fubao Wang; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jon Condra; Xiaomei Liu; Richard Hampton; Andrea Carfi; Antonello Pessi; Elisabetta Bianchi; Joseph Joyce; Chris Lloyd; Romas Geleziunas; David Bramhill; Vicki M King; Adam C Finnefrock; William Strohl; Zhiqiang An
Journal:  MAbs       Date:  2009-09-08       Impact factor: 5.857

4.  Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.

Authors:  Yun Kenneth Kang; Sofija Andjelic; James M Binley; Emma T Crooks; Michael Franti; Sai Prasad N Iyer; Gerald P Donovan; Antu K Dey; Ping Zhu; Kenneth H Roux; Robert J Durso; Thomas F Parsons; Paul J Maddon; John P Moore; William C Olson
Journal:  Vaccine       Date:  2009-06-28       Impact factor: 3.641

5.  SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins.

Authors:  Chetan Sood; Mariana Marin; Ajit Chande; Massimo Pizzato; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2017-02-08       Impact factor: 5.157

6.  Designing a soluble near full-length HIV-1 gp41 trimer.

Authors:  Guofen Gao; Lindsay Wieczorek; Kristina K Peachman; Victoria R Polonis; Carl R Alving; Mangala Rao; Venigalla B Rao
Journal:  J Biol Chem       Date:  2012-11-26       Impact factor: 5.157

7.  Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies.

Authors:  Wen Yuan; Xing Li; Marta Kasterka; Miroslaw K Gorny; Susan Zolla-Pazner; Joseph Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  2009-03       Impact factor: 2.205

8.  Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.

Authors:  Elena Gustchina; Carole A Bewley; G Marius Clore
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

9.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

10.  Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth.

Authors:  Elena Gustchina; John M Louis; Christian Frisch; Francisco Ylera; Annette Lechner; Carole A Bewley; G Marius Clore
Journal:  Virology       Date:  2009-08-19       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.